#$%^&*AU2017203923A120170706.pdf#####1: rbr Interwoven NRPortbl DCC RBR 14757173_l.docx-9 06/2017 ABSTRACT The present invention relates to the use of a VEGF antagonist in the treatment of chorioretinal neovascular or permeability disorders in children. In particular, the invention provides a VEGF antagonist for use in a method for treating a child having CNV or ME, wherein said method comprises administering to the eye of a child a VEGF antagonist that either does not enter or is rapidly cleared from the systemic circulation. The VEGF antagonist may be administered intravitreally, e.g. through injection, or topically, e.g. in form of eye drops. The invention further provides the use of a VEGF antagonist in the manufacture of a medicament for treating a child having a chorioretinal neovascular or permeability disorder.WO 2015/004616 PCT/IB2014/062978 Figure 1 0. 5 0A4 0,3 0,2 0.5 0.4 0 3 E C0 O 05 40.3 0.2 0, 1 03 0,2 0 1 0.05 0.1 .2 05 Ratio of candidate Cmax and IC50 1/2
